Table 2.

Antibodies to adalimumab and mucosal healing in inflammatory bowel disease.

IBD type	No.	Previous anti-TNF, %	ATA titre cut-off	ATA [+], % MH vs no MH	p-Value	Assay	Ref.
CD	60	60	1U/ml	2.9 vs 28	0.03	HMSA	[4]
CD / UC	66 [CD: 59]	64	0.55U/ml	13.8 vs 37.8	0.03	HMSA	[5]
CD / UC	67 [CD: 58]	42	1.7 μg/ml	33.3 vs 56.4a	0.13	ELISAb	[6]
CD / UC	40 [CD: 22]	NR	10ng/ml	6.2 vs 33.3	0.06	ELISAc	[7]

IBD, inflammatory bowel disease; No., number of patients; ELISA, enzyme-linked immunosorbent assay; CD, Crohn’s disease; UC, ulcerative colitis; HMSA, homogeneous mobility shift assay; Ref., reference; NR, not reported; TNF, tumour necrosis factor; ATA, antibodies to adalimumab; U, units; MH, mucosal healing.

^aWith adequate drug concentrations [> 4.9 μg/ml].

^bAnti-human lambda chain detection ELISA.

^cLisa-Tracker Premium ELISA kit [Theradiag, Marne la vallée, France].